Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
BioArctic AB Class B ( ($SE:BIOA.B) ) has provided an update.
At its Annual General Meeting, BioArctic AB resolved to carry forward SEK 889,598,575 without paying dividends for 2024, re-elected its board members, and approved remuneration for them. The meeting also authorized the board to issue new shares and introduced a three-year incentive program for employees, which includes performance-based share units contingent on meeting specific conditions related to shareholder returns, operational targets, and sustainability goals.
More about BioArctic AB Class B
BioArctic AB is a Swedish biopharmaceutical company focused on developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. The company is known for its innovative research and development efforts in the biotechnology sector, aiming to address unmet medical needs in the field of neurodegenerative disorders.
Average Trading Volume: 290,954
Current Market Cap: SEK16.38B
Find detailed analytics on BIOA.B stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue